-
Mashup Score: 0
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers - 1 day(s) ago
A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
#Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers #radiology #imaging https://t.co/lyaPwBwuoi
-
-
Mashup Score: 1
The recall was put in place due to a leak risk that could make the therapies less effective and potentially lead to an infection.
Source: cardiovascularbusiness.comCategories: General Medicine News, Cardiology News and JournTweet-
Pfizer announces recall of 2 drugs, including 1 for #hypertension, over safety concerns #cardiology #cardiotwitter https://t.co/0VBvktXepl
-
-
Mashup Score: 0FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders - 4 day(s) ago
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders #cardiology #pharmacy https://t.co/LuiMrPfpFk
-
-
Mashup Score: 1Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD - 4 day(s) ago
CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
#Cardiology, #radiology specialists debate CCTA’s rise as a go-to #imaging modality for #CAD https://t.co/IBtJuXZ84r
-
-
Mashup Score: 5
Back in 2019, the FDA issued a warning about the use of paclitaxel-coated devices when treating peripheral artery disease. The agency took back that warning in 2023, but it appears to have made a significant impact on patient care.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
Momentary concerns over paclitaxel-coated devices may have put PAD patients at risk @SCAI @JACCjournals @ACCinTouch @ACCmediacenter https://t.co/hvNCHdcXYn
-
-
Mashup Score: 4
The procedure, performed on Feb. 14, was part of an early feasibility trial developed with help from the FDA.
Source: cardiovascularbusiness.comCategories: General Medicine News, Cardiology News and JournTweet-
World’s first patient treated with new implantable device for pulmonary hypertension #cardiology #cardiotwitter @StVincentIN @a_hittinger @shwinner https://t.co/gdZWxE4Oba
-
-
Mashup Score: 0
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
Advancing #AI for vascular surgery will require a commitment to data integrity @VascularSVS #cardiology https://t.co/qXZcqmTKi9
-
-
Mashup Score: 1
An additional 15 patients will now receive BiVacor’s titanium total artificial heart technology as they wait for a permanent transplant.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
‘Incredibly rewarding’: FDA expands total artificial heart study after early success #cardiology @bivacor https://t.co/FApPduXidz
-
-
Mashup Score: 0FDA announces recall of cryoablation catheters after multiple injuries, including 4 deaths - 6 day(s) ago
Boston Scientific is recalling the catheters associated with its POLARx Cryoablation System due to a heightened risk of esophageal injury. The FDA has ruled that this a Class I recall.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
FDA announces recall of cryoablation catheters after multiple injuries, including 4 deaths. #EPeeps #EPlab https://t.co/pXt06Sf4En
-
FDA’s tirzepatide decision creates uncertainty for patients—and results in a lawsuit https://t.co/moqy3RUf06